All In Biotech

Drug Trial Radar · NCT03589326

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 245 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

245

Actual

Start

Oct 4, 2018

Primary completion

Aug 12, 2022

Study completion Jul 31, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jul 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs of disease. Participants will take tablets of either ponatinib or imatinib at the same time each day combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue with single-agent therapy (ponatinib or imatinib) until they meet the discontinuation criteria from the study.

Conditions

  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Interventions

  • PonatinibDrug

    Ponatinib Tablets.

  • ImatinibDrug

    Imatinib Tablets.

  • VincristineDrug

    Vincristine IV injection.

  • DexamethasoneDrug

    Dexamethasone Tablets.

  • CytarabineDrug

    Cytarabine IV infusion.

  • MethotrexateDrug

    Methotrexate IV infusion.

  • PrednisoneDrug

    Prednisone Tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction PhaseTime frame: From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length = 28 days)

Locations

92 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • City of Hope - Duarte

    Duarte, California

  • University of California Los Angeles

    Los Angeles, California

  • Augusta University Georgia Cancer Center

    Augusta, Georgia

  • Indiana University

    Indianapolis, Indiana

  • Indiana Blood & Marrow Transplantation

    Indianapolis, Indiana

  • University of Kansas Medical Center Research Institute

    Kansas City, Kansas

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Monter Cancer Center

    New Hyde Park, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • Oregon Health and Science University

    Portland, Oregon

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Methodist Hospital

    San Antonio, Texas

  • Sanatorio Allende

    Córdoba, Argentina

  • Hospital Privado Centro Medico de Cordoba

    Córdoba, Argentina

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Universitaetsklinik Fuer Innere Medizin I

    Vienna, Austria

  • Hanusch Krankenhaus Wiener Gebietskrankenkasse

    Vienna, State of Vienna, Austria

  • Ordensklinikum Linz Elisabethinen

    Linz, Upper Austria, Austria

  • HEMORIO Instituto Estadual de Hematologia Arthur Siqueira de Cavalcanti

    Rio de Janeiro, Brazil

  • Instituto do Cancer do Estado de Sao Paulo

    São Paulo, Brazil

  • Fundacao Antonio Prudente - A.C.Camargo Cancer Center

    São Paulo, Brazil

  • Hospital Sao Rafael-Monte Tabor

    Salvador, Estado de Bahia, Brazil

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil

  • Hospital da Cidade

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hemocentro Campinas Unicamp

    Campinas, São Paulo, Brazil

  • Fundacao Doutor Amaral Carvalho

    Jaú, São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da Riberao Preto da Universidade de Sao Paulo

    Ribeirão Preto, São Paulo, Brazil

  • University Multiprofile Hospital for Active Treatment Saint Ivan Rilski

    Sofia, Sofia, Bulgaria

  • 855 West 12th Avenue

    Vancouver, British Columbia, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Hopital Charles-LeMoyne

    Greenfield Park, Quebec, Canada

  • Hopital Maisonneuve-Rosemont

    Montreal, Quebec, Canada

  • Institute of Hematology & Blood Diseases Hospital of CAMS & PUMC

    Tianjin, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.